Lipidor AB

LIPI

SE0012558617

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 07:53:54 28/05/2024 pm IST			5-day change	1st Jan Change
0.224 ^SEK	-7.44%		+1.82%	-55.56%

22/04	Lipidor AB Postpones the Publication of Annual Report for 2023	CI
21/03	Lipidor AB Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2	CI

Lipidor AB Announces Subsidiary Emollivet AB's Recruitment of Stina Linge as CEO

July 07, 2020 at 12:00 pm IST

Lipidor AB announced that the subsidiary Emollivet AB has recruited Stina Linge as CEO. Stina Linge joins Emollivet from her most recent role as Head of Startup Programs at Chalmers Ventures. Stina will take up her position on September 2, 2020.

Latest news about Lipidor AB

Lipidor AB Postpones the Publication of Annual Report for 2023	22/04	CI
Lipidor AB Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2	21/03	CI
Lipidor AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
Lipidor Seeks Approval for Late-stage Study of Plaque Psoriasis Medicine in India	20/12	MT
Lipidor Applies to the Indian Medical Products Agency to Start A Phase III study of AKP02G2	20/12	CI
Lipidor AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	22/11	CI
Lipidor Files New Patent Application for Akvano Technology in EU	27/23/27	MT
Lipidor AB Files New Patent Application with the European Patent Office	27/23/27	CI
Lipidor, Relife Adds Asia Pacific to Psoriasis Treatment License Deal	18/23/18	MT
Lipidor AB Extends and Expands Cooperation with Relife	18/23/18	CI
Lipidor AB Signs Agreement with Cliantha Research to Conduct A Phase III Study with the Drug Candidate Akp02g2, for the Treatment of Psoriasis	20/23/20	CI
Lipidor AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23/23/23	CI
Lipidor AB Confirms Clinical Plan for New Version of Akp02	22/23/22	CI
Lipidor AB Updates on Development of AKP02	26/23/26	CI
Lipidor AB Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Lipidor AB Auditor Raises 'Going Concern' Doubt	26/23/26	CI
Lipidor AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	22/23/22	CI
Lipidor AB Reports Earnings Results for the Full Year Ended December 31, 2022	22/23/22	CI
Lipidor AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	23/22/23	CI
Lipidor AB Provides Update Following Outcome of Phase Iii Study of Psoriasis Candidate Akp02	15/22/15	CI
Lipidor AB Announces Results from the Its Clinical Phase III Study of AKP02 for Psoriasis	28/22/28	CI
Lipidor Updates on Phase III Clinical Study of Psoriasis Candidate AKP02	29/22/29	CI
Lipidor AB Appoints Charlotta Ekman as Chief Financial Officer, with Effect from October 1, 2022	25/22/25	CI
Lipidor AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	24/22/24	CI
Lipidor AB Announces All Patients in Lipidor's Phase III Study with Psoriasis Candidate Akp02 Have Completed Treatment	23/22/23	CI

Chart Lipidor AB

Duration

Period

More charts

Company Profile

Lipidor AB is a Sweden-based drug delivery company focusing on topical medication. The Company is focused to develop, patent and commercialize formulation concepts and technologies based on lipids. The Company develops product concepts based on AKVANO technology, which represents a dosage form that creates a lipid layer on the skin surface for effective delivery of drugs and skin care treatment. The Companyâs cooperation partners include Cerbios-Pharma, which specializes in the development and manufacturing of chemical and biological active pharmaceutical ingredients (APIs), and Aurena Laboratories AB, a manufacturer of bag-on-valve aerosol sprays for the pharmaceutical and medical device industry.

Sector

Pharmaceuticals

Calendar

05/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIPIDOR AB	-55.56%	7L
ELI LILLY AND COMPANY	+37.88%	73TCr
JOHNSON & JOHNSON	-7.89%	35TCr
MERCK & CO., INC.	+15.43%	33TCr
ABBVIE INC.	-0.43%	28TCr
ASTRAZENECA PLC	+13.47%	24TCr
NOVARTIS AG	+7.35%	21TCr
ROCHE HOLDING AG	-6.42%	20TCr
AMGEN INC.	+4.08%	16TCr
PFIZER, INC.	-1.95%	16TCr

Other Pharmaceuticals

Lipidor AB

Equities

LIPI

SE0012558617

Pharmaceuticals

Lipidor AB Announces Subsidiary Emollivet AB's Recruitment of Stina Linge as CEO

Latest news about Lipidor AB

Chart Lipidor AB

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals